EPO and anemia (phenotype): Crisà et al. [34] retrospectively evaluated fifty-nine patients who received ruxolitinib combined with ESAs for anemia and had found that the rate of anemia may be related to the combination of ruxolitinib and ESAs, and lower erythropoietin (EPO) (< 125u/I) level was an obvious predictor of anemia response.